Stop Waiting for Rescue: The New Rules of Cannabis Finance

Takeaways

- *The cannabis equity drought is structural*, not cyclical. Operators
are playing a financing game that no longer exists.
- *“Toxic hope” delays strategy*, costing runway, leverage, and control
over exit options.
- *Betting on political timelines isn’t a capital plan*; operators need
structures that work under current law.
- *Alternative ownership structures can change the math* by addressing
the 280E drag and creating new liquidity pathways.

Hope usually is considered an asset. But for the cannabis industry, hope
quietly has become one of its most dangerous liabilities.

Every operator needs to confront one hard question in 2026: *Is hope
harming my ability to raise capital? *Across the sector, founders are
holding onto a familiar set of expectations that may no longer hold true:

- Federal reform will arrive soon enough to rescue margins.
- Investors are just “waiting on the sidelines.”
- The equity markets that existed five years ago will reappear.

This kind of optimism isn’t helping anyone. It isn’t motivating strategic
thinking or unlocking new financing avenues. It’s simply delaying shifts
the industry desperately needs to make.

The problem isn’t that cannabis is unloved. The problem is that cannabis
operators are playing a financing game that no longer exists.
The math has changed: why the equity drought is structural

For years, many plant-touching operators have believed the capital freeze
was cyclical. It isn’t. Today’s drought persists because the underlying
logic of equity investing collapses under the weight of cannabis-specific
constraints.

Start with Internal Revenue Code Section 280E. It doesn’t “compress”
earnings; it eliminates them. Investors don’t buy equity for the privilege
of funding a tax obligation that consumes 60 to 70 percent of what should
be net income. No sophisticated investor can price future earnings when
future earnings don’t exist.

Add to that a regulatory environment where pricing, margins, and even basic
operating rules shift unpredictably. Equity investment depends on
predictable risk and definable upside. Cannabis offers neither. Even in a
stronger macro environment, the capital that once poured into the industry
was subsidized by somewhat cheap money, novelty, and optimism. Those
conditions are gone, and super-high interest rates have only magnified the
mismatch between investor expectations and cannabis realities.

The hope capital will come back is built on a misunderstanding. Investors
didn’t retreat because of sentiment. They retreated because the math
stopped working.
The cost of waiting: when optimism replaces strategy

This is where “toxic hope” comes in. It looks like confidence, but it
functions like denial.

Operators tell themselves everything will change once the Secure and Fair
Enforcement Regulation (SAFER) Banking Act passes, or once the next
election cycle kicks in, or once the market “stabilizes.” But this waiting
game is costing founders runway, bargaining power and, in many cases, the
opportunity to control their own exit.

I’ve spoken with operators who delayed restructuring for two full years
because they expected equity markets to thaw. Others kept refinancing
expensive debt under the assumption that a fresh round of investors would
bail them out. Others are waiting for some random buyer to come in and pay
them all cash (as if). Some are still building pitch decks for investors
who simply cannot invest under present conditions — not because they lack
interest, but because the risk profile is structurally incompatible with
equity economics.

Hope becomes toxic the moment it replaces strategy. In cannabis, that
moment arrived years ago. Too many operators just didn’t notice.
The exit myth: why standard investment logic fails

Even now, many founders approach capital strategy as if cannabis behaves
like any other emerging consumer industry. However, cannabis remains
fundamentally defined by a tax code that penalizes normal business
operations, regulatory fragmentation, and restricted capital channels. The
industry simply does not fit into the equity investing frameworks into
which founders keep trying to insert themselves.

Institutional investors want predictable earnings, a reliable cost
structure, and an obvious exit. Cannabis provides none of those. That will
remain true until the structural conditions change, and betting a company’s
future on political timelines is not strategy.

This is why operators who continue to wait for equity markets to return are
not making a rational long-term bet. They’re holding onto a financing model
that isn’t coming back in any recognizable form.
Engineering the fix: why your architecture must change

If the traditional model is broken, the question becomes “what actually
works?”

This is where alternative structures, especially employee stock-ownership
plans (ESOPs), shift the financial landscape. An ESOP is not a tax trick or
a feel-good employee incentive program. Done correctly, it’s a structural
business re-engineering that removes the single biggest financial drag on
cannabis operators: income tax under 280E.

When a cannabis company becomes 100-percent ESOP-owned, its federal income
tax obligation and state income tax obligation both drop to zero. That
transformation alone changes the trajectory of the company. A business that
was barely cash-flow-positive becomes meaningfully profitable. A founder
who was boxed out of traditional exits suddenly has a pathway to liquidity
without selling to a consolidator or diluting their share of the business
into irrelevance. Employees become shareholders, boosting retention and
alignment. And, critically, an ESOP does not rely on speculative federal
reform or the return of outside equity.

This isn’t optimism. This is architecture. It’s a solution grounded in the
tax code.
Overcoming the friction: debunking alternative model myths

Resistance to ESOPs usually is rooted in misconceptions like they’re too
complicated, employees will run the company, they depress valuation, or
they work only for large companies. None of these presumptions are true.
Many founders are uncomfortable moving away from the financing frameworks
they’ve always known. They don’t want to consider an alternative because
they’re still holding onto hope that the old world will return. But that
hope is costing them money, often millions, while the ESOP path creates
liquidity, eliminates the tax burden, and preserves long-term upside.

The industry doesn’t need more optimism. It needs more operators willing to
confront financial reality and adjust accordingly.
The era of engineering: stop hoping and start acting

Toxic hope has been allowed to shape cannabis capital strategy for too
long. It’s time for founders to stop waiting for rescue and start
engineering outcomes.

Federal reform may come someday. Investor appetite may improve. But none of
that helps operators solve the problems they face today. What helps is
embracing structures that work under current law, current markets, and
current constraints.

If there’s one message the industry needs to hear in 2026, it’s this:Stop
hoping. Start acting. The path forward belongs to those willing to rethink
the game, not wait for it to change.
------------------------------
Cannabis finance, clarified

1. What does “toxic hope” mean in cannabis finance?

The phrase implies a habit of waiting for reform, investor return, or
market stabilization instead of restructuring and pursuing viable capital
architecture now.
2. Why isn’t cannabis equity coming back like it did before?

Because the underlying equity math is impaired by structural constraints
— especially 280E and unpredictable regulatory conditions.
3. What’s the biggest strategic cost of “waiting it out”?

Operators lose runway and bargaining power—and risk losing control of
the timing and terms of any exit.
4. Why do traditional exit assumptions fail in cannabis?

Investors want predictable earnings and a clear exit path; fragmentation
and tax/regulatory constraints distort both.
5. What kinds of structures can work under current law?

Alternative ownership/capital structures — particularly ESOPs — may
provide an “architecture” that can change the business trajectory without
relying on speculative reform.

------------------------------
[image: Darren Gleeman managing partner MBO Ventures]

As managing partner at MBO Ventures, serial entrepreneur and prolific angel
investor *Darren Gleeman* assists clients with employee stock ownership
plans (ESOPs) and capital management. Previously, he served as managing
partner at hedge fund GB Trading. Gleeman holds a patent on ESOP
methodology for the cannabis industry and received Green Market Report’s
2024 Top Financial Advisor award.